La Iniciativa en Medicaments Innovadors, IMI, ha publicat els títols dels topics que preveu incloure en les seves pròximes convocatòries:

- Patient perspective elicitation on benefits and risks of medicinal products, supplementing benefit risk assessments by regulators and HTAs (health technology assessments) from development through the entire life cycle
- Development of a quantitative system toxicology (QST) platform
- Diabetic kidney disease (DKD) biomarker idea
- Inflammation and Alzheimer’s disease (AD): modulating microglia function – focussing on TREM2 and CD33
- Enabling magnetic encephalography (MEG) as a biomarker for diagnosis and disease progression in mild cognitive impairment (MCI) and Alzheimer’s disease (AD)
- Understanding the role of amyloid biomarkers in diagnosis, clinical management and treatment of patients with cognitive impairment
- Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease
- Bringing apolipoprotein E (APOE) biology to validated Alzheimer’s disease targets

Tingueu en compte que aquesta informació és preliminar i que pot estar subjecta a canvis fins a la seva aprovació.
Més informació